EPIGEN BIOSCIENCES INC
- SAN DIEGO, CA 92121
- epigenbiosciences.com (company website, opens in a new tab)
- Corporate Entity (Not Tax Exempt)
- SAM active
- No verified credentials yet
- CMMCNot on file
- SPRSNone
- FCLVisible to paid members
Registration and small-business types: SAM.gov, synced Nov 9, 2026. Compliance: self-attested by the company unless marked verified. The SPRS chip shows a range, never the exact score. How verification works
- 36-mo obligations
- $0
- Awards on record
- 0
- Contract vehicles
- 0
- Verified credentials
- 0
Compliance posture: unverified (SAM.gov baseline only)
EPIGEN BIOSCIENCES INC has not claimed this profile. What you see comes from public SAM.gov and USAspending records; no one from the company has confirmed CMMC, SPRS or clearance details yet. Learn more about CMMC 2.0
About EPIGEN BIOSCIENCES INC
- Headquarters
- SAN DIEGO, CA 92121
Identifiers
UEI and CAGE come from SAM.gov. Other identifiers are listed by the company.
- UEIL1EDVCGK2327
- CAGE62HL2
Capabilities & differentiators
No capability narrative yet
Compliance posture
No compliance posture published yet
Facility clearance
Facility clearance: visible to paid members
Clearance levels are shown only to paying members; TeamingIndex does not advertise clearances (NISPOM 32 CFR 117.9). Learn more about facility clearances · Compare plans
Past performance
No federal prime awards on record
Contract vehicles
No contract vehicles on file
Proven teaming graph
No sub-award reports yet
Source: USAspending.gov sub-award reports (FSRS) (opens in a new tab) · sync date not recorded · Prime contractors report first-tier subcontracts of $30,000 or more. Amounts are reported sub-award values.
SBIR/STTR portfolio
SBIR/STTR awardee — Phase III-eligible for work derived from its SBIR/STTR projects
Agencies may award follow-on Phase III work without a new competition when it builds on this company’s earlier SBIR/STTR projects. Other work is competed as usual.
- Awards on record
- 25 awards
- Total awarded
- $20,235,589
- By phase
- SBIR Phase I: 13
- SBIR Phase II: 6
- STTR Phase I: 6
- By agency
- Department of Health and Human Services: 25
- Active projects
- 0 projects
- Projects whose contract end date is today or later.
- Phase II ending within 12 months
- 0 projects
- Phase II projects ending within 12 months. Agencies may award Phase III work without a new competition only when it derives from, extends or completes these projects.
- By year
- 2025: 1
- 2024: 1
- 2023: 2
- 2021: 4
- 2020: 2
- 2019: 2
- 2018: 3
- 2017: 2
- 2015: 1
- 2014: 4
- 2013: 1
- 2012: 2
Awards (most recent first)
Novel Methods for Nicotinic Receptor Modulation in the Treatment of Post-Operative Pain
STTR Phase I · Department of Health and Human Services (National Institutes of Health) · 2025 · $349,999
Sep 12, 2025 – Aug 31, 2026
Solicitation NS23-007 (2023) · Topic 300 · Research partner: UNIVERSITY OF CHICAGO
Novel Product Formulation toModulate Alpha7 Nicotinic Receptors for Therapy in Stroke Recovery
SBIR Phase I · Department of Health and Human Services (National Institutes of Health) · 2024 · $550,864
Jun 1, 2024 – May 31, 2025
Solicitation PA23-230 (2023) · Topic 105
Candidate selection of a LPAR1 antagonist for therapeutic application in NASH
SBIR Phase II · Department of Health and Human Services (National Institutes of Health) · 2023 · $2,013,280
Sep 1, 2023 – Jun 30, 2025
Solicitation PA22-176 (2022) · Topic 300
New Therapy for the Treatment of Primary Biliary Cholangitis.
SBIR Phase I · Department of Health and Human Services (National Institutes of Health) · 2023 · $448,110
May 1, 2023 – Apr 30, 2024
Solicitation PA22-176 (2022) · Topic 300
Lead candidate identification of LPAR1 antagonists for therapeutic application in NASH
SBIR Phase I · Department of Health and Human Services (National Institutes of Health) · 2021 · $397,398
Sep 20, 2021 – Sep 19, 2022
Solicitation PA20-260 (2020) · Topic 300
Evaluation of Alzheimers disease experimental small molecule therapeutics in the models of Amyotrophic lateral sclerosis
SBIR Phase I · Department of Health and Human Services (National Institutes of Health) · 2021 · $449,984
Jun 1, 2021 – May 31, 2022
Solicitation PA20-260 (2020) · Topic NIA
Selection of a lead LPAR1 antagonist for treatment of diabetic neuropathy
SBIR Phase II · Department of Health and Human Services (National Institutes of Health) · 2021 · $2,026,502
May 20, 2021 – Apr 30, 2023
- Direct to Phase II
Solicitation PA20-260 (2020) · Topic 200
Novel therapy for Fragile X syndrome
SBIR Phase II · Department of Health and Human Services (National Institutes of Health) · 2021 · $2,206,174
Apr 15, 2021 – Mar 31, 2023
Solicitation PA19-272 (2019) · Topic 101
Assessment of a selective kinase inhibitor in pre-clinical models of NASH
SBIR Phase I · Department of Health and Human Services (National Institutes of Health) · 2020 · $375,033
Sep 1, 2020 – Aug 31, 2021
Solicitation PA19-272 (2019) · Topic 300
Novel agents for idiopathic pulmonary fibrosis
SBIR Phase I · Department of Health and Human Services (National Institutes of Health) · 2020 · $299,983
May 1, 2020 – Apr 30, 2021
Solicitation PA19-272 (2019) · Topic NHLBI
Therapeutic in Situ Analgesic Implant for improved Oral-Facial Post-Operative Pain Outcomes
SBIR Phase I · Department of Health and Human Services (National Institutes of Health) · 2019 · $390,335
Sep 19, 2019 – Sep 18, 2020
Solicitation PA18-574 (2018) · Topic NIDCR
Lead optimization and development of novel targeted small molecule therapeutics for Alzheimers disease
SBIR Phase II · Department of Health and Human Services (National Institutes of Health) · 2019 · $2,171,366
Aug 15, 2019 – Apr 30, 2021
Solicitation PAS18-187 (2018) · Topic NIA
Assessment of LPA1R antagonists in animal models of NASH
SBIR Phase I · Department of Health and Human Services (National Institutes of Health) · 2018 · $298,946
Sep 5, 2018 – Aug 31, 2019
Solicitation PA18-574 (2018) · Topic 300
New Approach to Atopic Dermatitis
SBIR Phase I · Department of Health and Human Services (National Institutes of Health) · 2018 · $225,000
Sep 1, 2018 – Aug 31, 2019
Solicitation PA17-302 (2017) · Topic NIAMS
Development of a novel therapeutic for the treatment of diabetic nephropathy and renal fibrosis
SBIR Phase II · Department of Health and Human Services (National Institutes of Health) · 2018 · $2,998,612
Jun 20, 2018 – May 31, 2021
Solicitation PA17-302 (2017) · Topic 400
Novel Treatment for Traumatic Brain Injury
STTR Phase I · Department of Health and Human Services (National Institutes of Health) · 2017 · $417,267
Sep 28, 2017 – Aug 31, 2019
Solicitation PA16-303 (2016) · Topic 101 · Research partner: UNIVERSITY OF NORTH TEXAS HLTH SCI CTR
Novel therapy for Fragile X syndrome
STTR Phase I · Department of Health and Human Services (National Institutes of Health) · 2017 · $834,798
Sep 15, 2017 – Jul 31, 2019
Solicitation PA16-302 (2016) · Topic 101 · Research partner: UNIVERSITY OF CALIFORNIA, SAN DIEGO
Novel integrin inhibitors for kidney fibrosis
SBIR Phase I · Department of Health and Human Services (National Institutes of Health) · 2015 · $228,661
Sep 15, 2015 – Aug 31, 2016
Solicitation PA14-071 (2015) · Topic 400
Development of novel agents for the treatment of renal fibrosis adminstrative supplement
SBIR Phase II · Department of Health and Human Services (National Institutes of Health) · 2014 · $1,453,632
Sep 1, 2014 – Dec 31, 2016
Solicitation PA16-287 (2019) · Topic 300
Discovery of novel small molecule analgesics
STTR Phase I · Department of Health and Human Services (National Institutes of Health) · 2014 · $244,999
Solicitation PA13-235 (2014) · Topic NINDS · Research partner: UNIVERSITY OF CALIFORNIA SAN DIEGO
Novel Therapeutic Opportunity in Stroke
STTR Phase I · Department of Health and Human Services (National Institutes of Health) · 2014 · $225,000
Solicitation PA13-235 (2014) · Topic NINDS · Research partner: UNIVERSITY OF NORTH TEXAS HLTH SCI CTR
Synthesis and evaluation of novel kinase inhibitors as anti-metastasis agents for
SBIR Phase I · Department of Health and Human Services (National Institutes of Health) · 2014 · $225,000
Solicitation PA13-088 (2014) · Topic NCI · Research partner: Stub
High-specificity affinity reagents for N-glycosylation site mapping and glycomics
SBIR Phase I · Department of Health and Human Services (National Institutes of Health) · 2013 · $288,297
Solicitation PA12-088 (2013) · Topic NCI · Research partner: Stub
Drug regulators of nitric oxide production as Alzheimer's disease therapeutics
STTR Phase I · Department of Health and Human Services (National Institutes of Health) · 2012 · $726,746
Solicitation PAR09-259 (2012) · Topic NIA · Research partner: UNIVERSITY OF TEXAS HLTH SCI CTR HOUSTON
Selective LPA1 receptor antagonists as agents in prevention of renal fibrosis
SBIR Phase I · Department of Health and Human Services (National Institutes of Health) · 2012 · $389,603
Solicitation PA11-096 (2012) · Topic NIDDK · Research partner: Stub
Source: SBIR.gov award data file (opens in a new tab) · as of Nov 12, 2026 · file published Nov 1, 2026
FedRAMP offerings
No FedRAMP Marketplace listing
Source: FedRAMP Marketplace (opens in a new tab) · sync date not recorded
Exclusions & screening
SAM.gov exclusions
Not yet checked against SAM.gov exclusions.
Agencies generally may not award to excluded parties, and primes may not subcontract with them above the threshold in FAR 52.209-6 (except COTS items) without a compelling reason reported to the contracting officer (FAR 9.405, 9.405-2). Some exclusion types apply only to specific programs: read the record on SAM.gov.
Source: SAM.gov Exclusions (opens in a new tab) · sync date not recorded
Consolidated Screening List
No confirmed match on the Consolidated Screening List (screened Nov 13, 2026).
The list combines Commerce, State and Treasury export-control and sanctions lists. A “no match” result is a name-and-address screen, not an export-compliance determination.
Source: ITA Consolidated Screening List (opens in a new tab) · as of Nov 13, 2026
GSA CALC+ rate benchmark
No GSA CALC+ rates on record
Source: GSA CALC+ awarded ceiling rates (opens in a new tab) · sync date not recorded
NAICS, PSC & socio-economic status
NAICS codes
- 325199Title not in the curated listPrimary
SAM.gov does not report this entity as small under any listed NAICS code.
Socio-economic status
No socio-economic certifications reported in SAM.gov.
Product & service codes (PSC)
No PSC codes reported.
Teaming preferences
This company has not published teaming preferences.
Business development contact
No BD contact published
Corporate hierarchy
No parent entity reported in SAM.gov.
SBA counts affiliates when it determines whether a business is small (13 CFR 121.103), so a parent’s size can matter for set-aside work.
Data sources & provenance
SAM.gov
Registration, CAGE, NAICS, socio-economic status, corporate hierarchy and exclusions. Last synced Nov 9, 2026.
USAspending.gov
Prime award history and obligations (FPDS), synced nightly.
The contractor
Nothing yet: this profile has not been claimed by the company.
TeamingIndex verification
Credentials marked Verified were checked by a TeamingIndex reviewer; everything else is self-attested.
Corrections
Corrections to SAM.gov data must be made in SAM.gov; TeamingIndex picks them up on the next nightly sync. Go to SAM.gov (opens in a new tab)
Machine-readable: capability.md schema.org JSON-LD embedded in this page.
Zero CUI: TeamingIndex stores verification metadata only, never System Security Plans, POA&Ms or DD Form 254s.
Teaming
Ready to team with EPIGEN BIOSCIENCES INC?
Send an introduction and propose a mutual NDA. Their team is notified right away, and you can share the capability statement with your capture team.